PPT-Anticoagulation for VTE: How Long?

Geoffrey Barnes MD MSc University of Michigan GBarnesMD May 14 2020 Disclosures Grants PfizerBristolMyers Squibb Blue Cross Blue Shield of Michigan NHLBI AHRQ Consulting PfizerBristolMyers Squibb Janssen Portola AMAG Pharmaceuticals. Seven. Venous Disease Coalition. Long-Term Management of VTE. VTE . T. oolkit. Long-Term Treatment of DVT/PE:. 2 options. VTE . T. oolkit. LMWH S/C. Oral Anticoagulation (INR 2.0 - 3.0). 5-7 d. 3 . Brandon . McMahon,. MD. Venous . Thromboembolism. (VTE). ~950,000 cases of VTE annually (incident + recurrent). Rates expected to double by 2050. Mortality. 100,000 US deaths annually. 10-30% die within a month of diagnosis. Stacey Graven, ACNP. Vascular Surgery, Springfield Clinic. Springfield, Illinois. VTE. In September 2008, Surgeon General issued a “Call to Action to Prevent Deep Venous Thrombosis and Pulmonary Embolis. . . Feb 08/2014. Hanadi. . Alhozali,MBBS,ABIM,FRCPC. Assistant professor consultant internal medicine and Nephrology KAUH/Jeddah. Glomerular- based disease and Renal disease in pregnancy. Objectives. CHEST Guidelines 2016. Jennifer . Mah. , MD. March 2016. Case. A 44-year-old man is evaluated in follow-up for an episode of unprovoked left proximal leg deep venous thrombosis 3 months ago. Following initial anticoagulation with low-molecular-weight heparin, he began treatment with . . . Feb 08/2014. Hanadi. . Alhozali,MBBS,ABIM,FRCPC. Assistant professor consultant internal medicine and Nephrology KAUH/Jeddah. Glomerular- based disease and Renal disease in pregnancy. Objectives. Fibrillation. Michelle Tsukamoto . DSR 2 May 9, 2018. PGY 2. 1. Objectives. Discuss which patients with . atrial. fibrillation should be . anticoagulated. for CVA prevention. Learn about different oral anticoagulation options . Fibrillation. Michelle Tsukamoto . DSR 2 May 9, 2018. PGY 2. 1. Objectives. Discuss which patients with . atrial. fibrillation should be . anticoagulated. for CVA prevention. Learn about different oral anticoagulation options . . Alan Brush, MD, FACP. Chief, Anticoagulation Management Service. Harvard Vanguard Medical Associates. Language. . .. Suggestions . vs. . Recommendations: . based on the weight of evidence. Loading . Thomas W. Butler, M.D., F.A.C.P.. Associate Professor of Clinical Interdisciplinary Oncology. University of South Alabama. Mitchell Cancer Institute. June 22, 2017. Thomas W. Butler, M.D.. Nothing to disclose. An Educational Slide Set . American Society of Hematology 2018 Guidelines . for Management of Venous Thromboembolism. Slide set authors: . E. ric. Tseng MD, . MScCH. , University of Toronto and . Paul . and Pulmonary Embolism. An Educational Slide Set . American Society of Hematology 2020 Guidelines for Management of Venous Thromboembolism. Slide set authors: . Zachary . Liederman. MD . MScCH. (University of Toronto).  . Joshua P. Rainey. 1,3. , Olivia R. Palmer. 2. , Cathy Luke. 3. , José A. Diaz. 3. .  . 1. University of Michigan Medical School; . 2. Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI; . A review of quality improvement initiatives. 16 June 2022. Background . Anticoagulants include unfractionated and low molecular weight heparins, vitamin K antagonists and direct oral anticoagulants (DOAC)..